ANSWER AND REASONINGA. Do not treat the negative test as exclusion; pursue the planned tissue-diagnosis pathway
A negative result reduces probability but does not override a high-risk clinical context. The decision threshold for further investigation depends on the residual risk and harm of missed disease.
Why every option is right or wrong
A. Do not treat the negative test as exclusion; pursue the planned tissue-diagnosis pathway: A negative result reduces probability but does not override a high-risk clinical context. The decision threshold for further investigation depends on the residual risk and harm of missed disease.
B. Discharge because the test is negative: This confuses a reduced probability with a zero probability.
C. Repeat the same test indefinitely: Repetition without changing the diagnostic strategy may not resolve residual risk.
D. Start definitive treatment without diagnosis: Oncological treatment normally requires appropriately obtained tissue and staging.
E. Ignore the original clinical assessment: Pre-test probability is central to interpretation.
What if the scenario changed?
If pre-test probability were low and residual risk fell below a safe investigation threshold, observation with safety-netting could be reasonable.